Satellos Bioscience Inc
XTSX:MSCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ADC Therapeutics SA
NYSE:ADCT
|
CH |
|
Kaveri Seed Company Ltd
NSE:KSCL
|
IN |
|
China First Heavy Industries
SSE:601106
|
CN |
|
E
|
Etga Group Ltd
TASE:ETGA
|
IL |
|
Rumble Resources Ltd
ASX:RTR
|
AU |
|
HDC Hyundai Development Co
KRX:294870
|
KR |
|
Fenerbahce Futbol AS
IST:FENER.E
|
TR |
|
P
|
Premier Synthetics Ltd
BSE:509835
|
IN |
|
M
|
Marks Electrical Group PLC
LSE:MRK
|
UK |
|
Korn Ferry
NYSE:KFY
|
US |
|
Shaanxi Coal Industry Co Ltd
SSE:601225
|
CN |
|
J
|
Jiangsu New Energy Development Co Ltd
SSE:603693
|
CN |
|
AddLife AB
STO:ALIF B
|
SE |
Satellos Bioscience Inc
Total Current Assets
Satellos Bioscience Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Satellos Bioscience Inc
XTSX:MSCL
|
Total Current Assets
CA$2.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Current Assets
CA$84.3m
|
CAGR 3-Years
61%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Current Assets
$492m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
40%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Current Assets
$560.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
25%
|
CAGR 10-Years
25%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Current Assets
CA$85.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
137%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Current Assets
$201.4m
|
CAGR 3-Years
107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Satellos Bioscience Inc
Glance View
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is engaged in developing therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct dysregulated muscle stem-cell polarity, which balances replenishment of muscle stem cells and production of specialized tissue cells. The company uses MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders. The company also maintains two clinical stage products: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. iCo-008 provides treatment of the dermatological condition bullous pemphigoid (BP), atopic dermatitis, gastrointestinal conditions, and age-related macular degeneration (AMD). Oral Amphotericin B delivery system provides treatment of Visceral Leishmaniasis (VL).
See Also
What is Satellos Bioscience Inc's Total Current Assets?
Total Current Assets
2.2m
CAD
Based on the financial report for Dec 31, 2022, Satellos Bioscience Inc's Total Current Assets amounts to 2.2m CAD.
What is Satellos Bioscience Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
10%
Over the last year, the Total Current Assets growth was -59%. The average annual Total Current Assets growth rates for Satellos Bioscience Inc have been 15% over the past three years , 10% over the past five years .
